DE69233711D1 - Impfstoffe zur Behandlung von Kolonkrebs - Google Patents

Impfstoffe zur Behandlung von Kolonkrebs

Info

Publication number
DE69233711D1
DE69233711D1 DE69233711T DE69233711T DE69233711D1 DE 69233711 D1 DE69233711 D1 DE 69233711D1 DE 69233711 T DE69233711 T DE 69233711T DE 69233711 T DE69233711 T DE 69233711T DE 69233711 D1 DE69233711 D1 DE 69233711D1
Authority
DE
Germany
Prior art keywords
hormone
fragment
epitope
immunologically equivalent
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233711T
Other languages
English (en)
Inventor
Vernon C Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of DE69233711D1 publication Critical patent/DE69233711D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69233711T 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs Expired - Fee Related DE69233711D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92921753A EP0662839A4 (de) 1992-09-30 1992-09-30 Impfstoff und Antigenkonjugate.
PCT/US1992/008370 WO1994007530A1 (en) 1992-09-30 1992-09-30 Vaccines and antigenic conjugates

Publications (1)

Publication Number Publication Date
DE69233711D1 true DE69233711D1 (de) 2007-10-31

Family

ID=25677857

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233711T Expired - Fee Related DE69233711D1 (de) 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs

Country Status (7)

Country Link
EP (2) EP1129724B1 (de)
JP (1) JPH08502062A (de)
AT (1) ATE373486T1 (de)
AU (1) AU679902B2 (de)
CA (1) CA2145391A1 (de)
DE (1) DE69233711D1 (de)
WO (1) WO1994007530A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US7053177B1 (en) 1997-05-15 2006-05-30 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7135457B1 (en) 1997-05-15 2006-11-14 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
WO2000041717A2 (en) * 1998-12-18 2000-07-20 Avi Biopharma, Inc. Chorionic gonadotropin dna vaccines and methods
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US7235376B2 (en) 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
EP2567974A3 (de) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoklonale Antikörper gegen Progastrin
CN103169958A (zh) * 2005-02-04 2013-06-26 萨瓦克公司 存活蛋白肽疫苗
CA2612394C (en) 2005-06-15 2017-02-21 The Ohio State University Research Foundation Her-2 peptides
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
WO2011056226A1 (en) * 2009-11-05 2011-05-12 Mercia Pharma Llc Adjuvanted nanoparticulate influenza vaccine
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762913A (en) * 1973-05-07 1988-08-09 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US5006334A (en) * 1973-05-07 1991-04-09 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4310455A (en) * 1979-04-17 1982-01-12 Research Corporation Antigen for early pregnancy test and contraceptive vaccine
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
EP0662839A4 (de) 1995-09-06
JPH08502062A (ja) 1996-03-05
EP1129724B1 (de) 2007-09-19
EP1129724A2 (de) 2001-09-05
EP1129724A3 (de) 2001-11-07
ATE373486T1 (de) 2007-10-15
WO1994007530A1 (en) 1994-04-14
AU679902B2 (en) 1997-07-17
AU2806392A (en) 1994-04-26
EP0662839A1 (de) 1995-07-19
CA2145391A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
DE69233711D1 (de) Impfstoffe zur Behandlung von Kolonkrebs
PT92938A (pt) Imunogenes e processo para a preparacao de composicoes imunogenicas contra os peptidos da gastrina
GB2303854B (en) Helicobacter proteins and vaccines
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
DE69939706D1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
KR937000146A (ko) 거세되지 않은 수컷 가축의 고기의 관능적 품질을 개선하기 위한 방법, 이 방법에 이용 가능한 백신, 특히 그 백신을 생산하기 위한 신규의 펩티드 및 그에 관계된 백신반응 키트
NO883306L (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
EP0495008A4 (en) Method of treatment
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
HK1005541A1 (en) Treatment of helicobacter associated gastroduodenal disease
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
ES2071176T3 (es) Aparato magnetico para tratamiento de combustibles.
GR3029727T3 (en) Synthetic peptides and vaccines against parvovirus.
ATE134705T1 (de) Rekombinantes hyopneumoniae antigen und dessen verwendung
DK543988A (da) Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
DK0623170T3 (da) Vacciner baseret på streptokinase
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
DE69322960D1 (de) Empfängnisverhütender impfstoff
Moreno-Fierros et al. Effect of immunization with glutaraldehyde-fixed Entamoeba histolytica trophozoites on the proportions of IgA, IgM, and IgG B lymphocytes in the large and small intestine from Balb/c mice
KR980000469A (ko) Hbv 항원단백질을 발현하는 키메라 폴리오바이러스 백신벡터를 이용한 면역화 방법
DE69012328D1 (de) Srif-verwandte peptide und deren verwendungen.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee